A Randomized, Single-blind, Placebo-controlled, Parallel Group Study to Investigate the Effects of Intranasal RV568 (400microg) Administered Twice Daily to Adult Male Volunteers Experimentally Inoculated With Live Respiratory Syncytial Virus.

Trial Profile

A Randomized, Single-blind, Placebo-controlled, Parallel Group Study to Investigate the Effects of Intranasal RV568 (400microg) Administered Twice Daily to Adult Male Volunteers Experimentally Inoculated With Live Respiratory Syncytial Virus.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Sep 2013

At a glance

  • Drugs RV 568 (Primary)
  • Indications Respiratory syncytial virus infections; Respiratory tract infections
  • Focus Therapeutic Use
  • Sponsors RespiVert
  • Most Recent Events

    • 09 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
    • 10 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top